151 related articles for article (PubMed ID: 34465264)
21. PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-small-cell lung cancer.
Zinner RG; Obasaju CK; Spigel DR; Weaver RW; Beck JT; Waterhouse DM; Modiano MR; Hrinczenko B; Nikolinakos PG; Liu J; Koustenis AG; Winfree KB; Melemed SA; Guba SC; Ortuzar WI; Desaiah D; Treat JA; Govindan R; Ross HJ
J Thorac Oncol; 2015 Jan; 10(1):134-42. PubMed ID: 25371077
[TBL] [Abstract][Full Text] [Related]
22. Comparative Effectiveness of Pemetrexed-platinum Doublet Chemotherapy With or Without Bevacizumab as First-line Therapy for Treatment-naive Patients With Advanced Nonsquamous Non-small-cell Lung Cancer in China.
Li X; Abbas M; Li Y; Teng Y; Fang Y; Yu S; Wen Y; Wang L; Shi M
Clin Ther; 2019 Mar; 41(3):518-529. PubMed ID: 30846285
[TBL] [Abstract][Full Text] [Related]
23. A Randomized Phase II Study of Maintenance Bevacizumab, Pemetrexed or Bevacizumab Plus Pemetrexed for Advanced Non-squamous Non-small Cell Lung Cancer.
Yoshida H; Kim YH; Sakamori Y; Nagai H; Ozasa H; Kaneda T; Yoshioka H; Nakagawa H; Tomii K; Okada A; Yoshimura K; Hirabayashi M; Hirai T
Anticancer Res; 2020 May; 40(5):2981-2987. PubMed ID: 32366452
[TBL] [Abstract][Full Text] [Related]
24. Bevacizumab in the treatment of NSCLC: patient selection and perspectives.
Russo AE; Priolo D; Antonelli G; Libra M; McCubrey JA; Ferraù F
Lung Cancer (Auckl); 2017; 8():259-269. PubMed ID: 29276417
[TBL] [Abstract][Full Text] [Related]
25. CD44 expression in the tumor periphery predicts the responsiveness to bevacizumab in the treatment of recurrent glioblastoma.
Nishikawa M; Inoue A; Ohnishi T; Yano H; Kanemura Y; Kohno S; Ohue S; Ozaki S; Matsumoto S; Suehiro S; Nakamura Y; Shigekawa S; Watanabe H; Kitazawa R; Tanaka J; Kunieda T
Cancer Med; 2021 Mar; 10(6):2013-2025. PubMed ID: 33543833
[TBL] [Abstract][Full Text] [Related]
26. Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial†.
Pujol JL; Lavole A; Quoix E; Molinier O; Souquet PJ; Barlesi F; Le Caer H; Moro-Sibilot D; Fournel P; Oster JP; Chatellain P; Barre P; Jeannin G; Mourlanette P; Derollez M; Herman D; Renault A; Dayen C; Lamy PJ; Langlais A; Morin F; Zalcman G;
Ann Oncol; 2015 May; 26(5):908-914. PubMed ID: 25688059
[TBL] [Abstract][Full Text] [Related]
27. Anti-vascular endothelial growth factor antibody attenuates inflammation and decreases mortality in an experimental model of severe sepsis.
Jeong SJ; Han SH; Kim CO; Choi JY; Kim JM
Crit Care; 2013 May; 17(3):R97. PubMed ID: 23710641
[TBL] [Abstract][Full Text] [Related]
28. Impact of bevacizumab in combination with erlotinib on EGFR-mutated non-small cell lung cancer xenograft models with T790M mutation or MET amplification.
Furugaki K; Fukumura J; Iwai T; Yorozu K; Kurasawa M; Yanagisawa M; Moriya Y; Yamamoto K; Suda K; Mizuuchi H; Mitsudomi T; Harada N
Int J Cancer; 2016 Feb; 138(4):1024-32. PubMed ID: 26370161
[TBL] [Abstract][Full Text] [Related]
29. Circulating vascular endothelial growth factor receptor 2/pAkt-positive cells as a functional pharmacodynamic marker in metastatic colorectal cancers treated with antiangiogenic agent.
Shin SJ; Hwang JW; Ahn JB; Rha SY; Roh JK; Chung HC
Invest New Drugs; 2013 Feb; 31(1):1-13. PubMed ID: 22539090
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of the Structural, Physicochemical, and Biological Characteristics of SB11, as Lucentis
Kim E; Han J; Chae Y; Park H; Kim S; Kim S; Lee J; Kim BC
Ophthalmol Ther; 2022 Apr; 11(2):639-652. PubMed ID: 35084693
[TBL] [Abstract][Full Text] [Related]
31. FDA's Approval of the First Biosimilar to Bevacizumab.
Casak SJ; Lemery SJ; Chung J; Fuchs C; Schrieber SJ; Chow ECY; Yuan W; Rodriguez L; Gwise T; Rowzee A; Lim S; Keegan P; McKee AE; Pazdur R
Clin Cancer Res; 2018 Sep; 24(18):4365-4370. PubMed ID: 29743182
[TBL] [Abstract][Full Text] [Related]
32. Bevacizumab combined with apatinib enhances antitumor and anti-angiogenesis effects in a lung cancer model
Wang M; Zeng Q; Li Y; Imani S; Xie D; Li Y; Han Y; Fan J
J Drug Target; 2020 Nov; 28(9):961-969. PubMed ID: 32374627
[TBL] [Abstract][Full Text] [Related]
33. Correlation between the qualification for bevacizumab use and the survival of patients with non-small cell lung cancer harboring the epidermal growth factor receptor mutation: a retrospective analysis.
Hakozaki T; Okuma Y; Hashimoto K; Hosomi Y
J Cancer Res Clin Oncol; 2019 Oct; 145(10):2555-2564. PubMed ID: 31350622
[TBL] [Abstract][Full Text] [Related]
34. Interleukin-6 as an enhancer of anti-angiogenic therapy for ovarian clear cell carcinoma.
Seki T; Yanaihara N; Shapiro JS; Saito M; Tabata J; Yokomizo R; Noguchi D; Kuroda T; Kawabata A; Suzuki J; Takahashi K; Matsuzawa H; Miyake M; Takenaka M; Iida Y; Yanagida S; Okamoto A
Sci Rep; 2021 Apr; 11(1):7689. PubMed ID: 33833265
[TBL] [Abstract][Full Text] [Related]
35. Comparative effects of bevacizumab, ranibizumab and pegaptanib at intravitreal dose range on endothelial cells.
Carneiro A; Falcão M; Pirraco A; Milheiro-Oliveira P; Falcão-Reis F; Soares R
Exp Eye Res; 2009 Mar; 88(3):522-7. PubMed ID: 19135441
[TBL] [Abstract][Full Text] [Related]
36. Randomized phase II study of pemetrexed or pemetrexed plus bevacizumab for elderly patients with previously untreated non-squamous non-small cell lung cancer: Results of the Lung Oncology Group in Kyushu (LOGIK1201).
Fukuda M; Kitazaki T; Ogawara D; Ichiki M; Mukae H; Maruyama R; Nakagaki N; Shimada M; Ikeda T; Kishimoto J; Harada T; Seto T; Ebi N; Takayama K; Okamoto I; Ichinose Y; Sugio K
Lung Cancer; 2019 Jun; 132():1-8. PubMed ID: 31097081
[TBL] [Abstract][Full Text] [Related]
37. SB8: A Bevacizumab Biosimilar.
Syed YY
Target Oncol; 2020 Dec; 15(6):787-790. PubMed ID: 33206282
[TBL] [Abstract][Full Text] [Related]
38. The efficacy and safety of pemetrexed plus bevacizumab in previously treated patients with advanced non-squamous non-small cell lung cancer (ns-NSCLC).
Ding L; Liu K; Jiang Z; Chen Q; Zhou N; Liang Y; Gao H; Hong X; Wu H
Tumour Biol; 2015 Apr; 36(4):2491-9. PubMed ID: 25417899
[TBL] [Abstract][Full Text] [Related]
39. Real world study of the continuation of bevacizumab beyond disease progression after first-line treatment containing bevacizumab in Chinese patients with advanced non-small cell lung cancer.
Xing P; Mu Y; Wang Y; Hao X; Zhu Y; Hu X; Wang H; Liu P; Lin L; Wang Z; Li J
Thorac Cancer; 2018 Dec; 9(12):1716-1724. PubMed ID: 30324773
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of bevacizumab (Bev) plus chemotherapy (CT) compared to CT alone in previously untreated locally advanced or metastatic non-small cell lung cancer (NSCLC): systematic review and meta-analysis.
Botrel TE; Clark O; Clark L; Paladini L; Faleiros E; Pegoretti B
Lung Cancer; 2011 Oct; 74(1):89-97. PubMed ID: 21377753
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
